Pharmacokinetics of the new potential antiparkinsonian agent ADK-1113 after different dosage regimens in mice

The pharmacokinetics of ADK-1113 were studied in mice treated with different dosage regimens.
Objective. This study aimed to investigate ADK-1113 pharmacokinetics after multiple intraperitoneal administrations.
Methods. This study was conducted on male outbred mice. The concentrations of ADK-1113 in the blood plasma were determined using high-performance liquid chromatography with mass-spectrometric detection. The pharmacokinetic parameters were evaluated using a model-independent method.
Results. The test substance in the blood plasma was determined for 4 h after single and multiple (four times with a dosage interval of 2.8 h) intraperitoneal administrations at a dose of 10 mg/kg. ADK-1113 administration mode did not affect its half-life or mean residence time. ADK-1113 did not accumulate in mice.

1. Guidelines for conducting preclinical studies of drugs. Part one. Metodicheskie rekomendacii po provedeniyu doklinicheskih issledovanij farmakokinetiki novyh lekarstvennyh sredstv. Ed by Mironov AN. Moscow: Grif and K, 2012. P. 865-880. (In Russ.). Доступно по: https://clck.ru/3BEMMg. Ссылка активна на 16.06.2025.

2. Кravtsova OYu, Dvoryaninov DА, Kolyvanov GВ, Litvin AА, Gribakina OG, Zherdev VР. Experimental pharmacokinetics of a new antiparkinsonian drug ADK-1113. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2024;(1):27-31. (In Russ.). doi: 10.37489/2587-7836-2024-1-27-31. END: KNFZMY.

3. Patent RUS RU 2 820 315 C1/24.06.03. Kapitsa IG, Voronina TA, et al. Adamantyl derivatives of benzimidazole, having antiparkinsonian activity. (In Russ.).

4. Sergienko VI, Gelliff R, Bondareva IB. Prikladnaya Pharmacokinetika. Moscow: RAMN, 2003. (In Russ.).

5. Kravtsova OYu, Dvoryaninov DA, Kolyvanov GB, et al. Quantification of a new antiparkinsonian agent ADK-1113 in mouse blood plasma by high performance liquid chromatography – tandem mass spectrometry. Exper. Clin. Pharmacol. 2024;87(2):6-12. (In Russ.). doi: 10/30906/0869-2092-2024-87-2-6-12.

6. Farmacokinetika. NN Karkishenko, VV Khoronko, SA Sergeeva, VN Karkishenko. Rostov-naDonu: Fenix, 2001. (In Russ.). ISBN 5-222-01504-1.

7. Miroshnichenko II. Osnovy farmacokinetiki. Moscow: Geotar-Med, 2002. (In Russ.). ISBN 5-9231-0211-0.

8. Tsaioun K, Kate SA ed. ADMET for medicinal chemists: a practical guide. New Jersey: John Wiley & Sons Inc., Hoboken; 2011.

9. Mensah JA, Johnson K, Reilly CA, et al. Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach. Epilepsia. 2022 Nov;63(11):2937-2948. doi: 10.1111/epi.17402.

10. Vogel HG ed. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Berlin: Springer Verlag, Heidelberg; 2011.